CLINICAL PROTOCOL AND DATA MANAGEMENT The Clinical Protocol and Data Management (CPDM) component includes the Clinical Protocol Office (CPO) and the compliance committees (Compliance, Data and Safety Monitoring). These groups provide centralized management and oversight for cancer clinical trials conducted by UNC Lineberger Comprehensive Cancer Center (LCCC) members. The CPDM delivers a full range of management and quality control services for investigator-initiated local and multi-center trials (IITs), industry or other sponsored trials, as well as those originating in the NCI such as the National Clinical Trials Network groups. CPDM centralizes the protocol registration, regulatory affairs, compliance committee work, and management of clinical trials, facilitates efficient and effective training for research personnel and monitors timely activation of protocols in support of LCCC investigators from all relevant disciplines. IIT development is facilitated by our Clinical Development Team made up of dedicated specialists. Carrie Lee, MD, MPH serves as Medical Director of the CPO, Claire Dees, MD, ScM, is the Faculty Director of the Clinical Development Team, and Matt Milowsky, MD, chairs the Clinical Trials Executive Committee composed of the disease-specific Protocol Office Disease (POD) faculty and other leaders. In 2019, interventional trials accrued 2799 patients including 733 accrued to treatment trials. Observational studies enrolled 656 patients, and 514 enrolled on ancillary/correlative trials. LCCC clinical trials enroll patients from the entire state of North Carolina, our catchment area. A unique feature of LCCC?s CPDM is the Clinical Development Team that assists investigators developing IITs in study concept development and design, funding applications, protocol writing, and adherence to regulatory requirements including IND support and management of FDA communications. With this team over the past 5 years we have increased our IITs by 30% and nearly doubled our LCCC-held INDs to 42. Trial review is facilitated by our PODs, endorsed trials undergo review by the Resource and Feasibility Team (RAFT) to ensure appropriate staffing and resources, then review by the Protocol Review Committee (PRC).Budget and contract development occur in parallel so that IRB review and contract execution can be as close as possible. The LCCC Data and Safety Monitoring Committee meets monthly to review trials, with the frequency of review based on risk and complexity as determined by the LCCC PRC. The CPDM supports independent audits of our IITs conducted by an external entity, the UNC Office of Clinical Trials (OCT). The Compliance Committee meets monthly to review audit findings and corrective and preventive action (CAPA) plans. UNC LCCC conducts research on minority health disparities and seeks new ways to optimize trials across underserved groups and the lifespan. Dr. Charlot, the CPDM faculty advisor for minority accrual, is activating plans to improve clinical trial participation of racial/ethnic minorities and socioeconomically disadvantaged populations, creating a valuable link between CPDM and COE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089823
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Mayer, Deborah K; Landucci, Gina; Awoyinka, Lola et al. (2018) SurvivorCHESS to increase physical activity in colon cancer survivors: can we get them moving? J Cancer Surviv 12:82-94
Huo, Dezheng; Perou, Charles M; Olopade, Olufunmilayo I (2018) Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply. JAMA Oncol 4:883-884
Howe, Chanelle J; Robinson, Whitney R (2018) Survival-related Selection Bias in Studies of Racial Health Disparities: The Importance of the Target Population and Study Design. Epidemiology 29:521-524
Byrne, James D; Yeh, Jen Jen; DeSimone, Joseph M (2018) Use of iontophoresis for the treatment of cancer. J Control Release 284:144-151
Wilkin, Timothy J; Chen, Huichao; Cespedes, Michelle S et al. (2018) A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis 67:1339-1346
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Ubil, Eric; Caskey, Laura; Holtzhausen, Alisha et al. (2018) Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. J Clin Invest 128:2356-2369
Hamad, Ahmad; Iweala, Onyinye I; Henderson, Cory et al. (2018) Recurrent anaphylaxis during cardiac catheterization due to ethylene oxide. J Allergy Clin Immunol Pract 6:2148-2150
Ho, G-T; Aird, R E; Liu, B et al. (2018) MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation. Mucosal Immunol 11:120-130
Pearce, Oliver M T; Delaine-Smith, Robin M; Maniati, Eleni et al. (2018) Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov 8:304-319

Showing the most recent 10 out of 1525 publications